Cargando…
ATAD2 interacts with C/EBPβ to promote esophageal squamous cell carcinoma metastasis via TGF-β1/Smad3 signaling
BACKGROUND: Distant metastasis is the leading cause of death for esophageal squamous cell carcinoma (ESCC) with limited treatment options and unsatisfactory effectiveness. Bromodomain (BRD) containing proteins are emerging targets for cancer therapy with promising effects. As a unique member of BRD...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7986551/ https://www.ncbi.nlm.nih.gov/pubmed/33757572 http://dx.doi.org/10.1186/s13046-021-01905-x |
_version_ | 1783668468179009536 |
---|---|
author | Cao, Lian-Jing Zhang, Yi-Jun Dong, Si-Qi Li, Xi-Zhao Tong, Xia-Ting Chen, Dong Wu, Zi-Yi Zheng, Xiao-Hui Xue, Wen-Qiong Jia, Wei-Hua Zhang, Jiang-Bo |
author_facet | Cao, Lian-Jing Zhang, Yi-Jun Dong, Si-Qi Li, Xi-Zhao Tong, Xia-Ting Chen, Dong Wu, Zi-Yi Zheng, Xiao-Hui Xue, Wen-Qiong Jia, Wei-Hua Zhang, Jiang-Bo |
author_sort | Cao, Lian-Jing |
collection | PubMed |
description | BACKGROUND: Distant metastasis is the leading cause of death for esophageal squamous cell carcinoma (ESCC) with limited treatment options and unsatisfactory effectiveness. Bromodomain (BRD) containing proteins are emerging targets for cancer therapy with promising effects. As a unique member of BRD family, the function and molecular mechanism of ATAD2 in cancer development is seldomly investigated. METHODS: The clinical impact of ATAD2 was assessed both at RNA and protein level in 75 and 112 ESCC patients separately. The biological function of ATAD2 was investigated in vitro and in vivo. Signaling pathway and downstream effectors of ATAD2 were identified by RNA sequencing, luciferase reporter, co-immunoprecipitation, chromatin immunoprecipitation, immunofluorescence and western blot assay. RESULTS: We found that elevated ATAD2 expression was significantly associated with lymph node metastasis, advanced clinical stage as well as poor survival of ESCC patients. Silencing ATAD2 significantly suppressed ESCC cell migration and invasion in vitro, and inhibited tumor growth and lung metastasis in vivo. Mechanically, we identified a new cofactor, C/EBPβ. ATAD2 directly interacted with C/EBPβ and promoted its nuclear translocation, which directly bound to the promoter region of TGF-β1 and activated its expression. Further, we demonstrated that TGF-β1 activated its downstream effectors in a Smad3 dependent manner. In addition, we further found that ATAD2 promoted ESCC metastasis through TGF-β signaling induced Snail expression and the subsequent epithelial-mesenchymal transition. CONCLUSION: Our findings demonstrated the pro-metastatic function of ATAD2 and uncovered the new molecular mechanism by regulating C/EBPβ/TGF-β1/Smad3/Snail signaling pathway, thus providing a potential target for the treatment of ESCC metastasis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13046-021-01905-x. |
format | Online Article Text |
id | pubmed-7986551 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-79865512021-03-25 ATAD2 interacts with C/EBPβ to promote esophageal squamous cell carcinoma metastasis via TGF-β1/Smad3 signaling Cao, Lian-Jing Zhang, Yi-Jun Dong, Si-Qi Li, Xi-Zhao Tong, Xia-Ting Chen, Dong Wu, Zi-Yi Zheng, Xiao-Hui Xue, Wen-Qiong Jia, Wei-Hua Zhang, Jiang-Bo J Exp Clin Cancer Res Research BACKGROUND: Distant metastasis is the leading cause of death for esophageal squamous cell carcinoma (ESCC) with limited treatment options and unsatisfactory effectiveness. Bromodomain (BRD) containing proteins are emerging targets for cancer therapy with promising effects. As a unique member of BRD family, the function and molecular mechanism of ATAD2 in cancer development is seldomly investigated. METHODS: The clinical impact of ATAD2 was assessed both at RNA and protein level in 75 and 112 ESCC patients separately. The biological function of ATAD2 was investigated in vitro and in vivo. Signaling pathway and downstream effectors of ATAD2 were identified by RNA sequencing, luciferase reporter, co-immunoprecipitation, chromatin immunoprecipitation, immunofluorescence and western blot assay. RESULTS: We found that elevated ATAD2 expression was significantly associated with lymph node metastasis, advanced clinical stage as well as poor survival of ESCC patients. Silencing ATAD2 significantly suppressed ESCC cell migration and invasion in vitro, and inhibited tumor growth and lung metastasis in vivo. Mechanically, we identified a new cofactor, C/EBPβ. ATAD2 directly interacted with C/EBPβ and promoted its nuclear translocation, which directly bound to the promoter region of TGF-β1 and activated its expression. Further, we demonstrated that TGF-β1 activated its downstream effectors in a Smad3 dependent manner. In addition, we further found that ATAD2 promoted ESCC metastasis through TGF-β signaling induced Snail expression and the subsequent epithelial-mesenchymal transition. CONCLUSION: Our findings demonstrated the pro-metastatic function of ATAD2 and uncovered the new molecular mechanism by regulating C/EBPβ/TGF-β1/Smad3/Snail signaling pathway, thus providing a potential target for the treatment of ESCC metastasis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13046-021-01905-x. BioMed Central 2021-03-23 /pmc/articles/PMC7986551/ /pubmed/33757572 http://dx.doi.org/10.1186/s13046-021-01905-x Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Cao, Lian-Jing Zhang, Yi-Jun Dong, Si-Qi Li, Xi-Zhao Tong, Xia-Ting Chen, Dong Wu, Zi-Yi Zheng, Xiao-Hui Xue, Wen-Qiong Jia, Wei-Hua Zhang, Jiang-Bo ATAD2 interacts with C/EBPβ to promote esophageal squamous cell carcinoma metastasis via TGF-β1/Smad3 signaling |
title | ATAD2 interacts with C/EBPβ to promote esophageal squamous cell carcinoma metastasis via TGF-β1/Smad3 signaling |
title_full | ATAD2 interacts with C/EBPβ to promote esophageal squamous cell carcinoma metastasis via TGF-β1/Smad3 signaling |
title_fullStr | ATAD2 interacts with C/EBPβ to promote esophageal squamous cell carcinoma metastasis via TGF-β1/Smad3 signaling |
title_full_unstemmed | ATAD2 interacts with C/EBPβ to promote esophageal squamous cell carcinoma metastasis via TGF-β1/Smad3 signaling |
title_short | ATAD2 interacts with C/EBPβ to promote esophageal squamous cell carcinoma metastasis via TGF-β1/Smad3 signaling |
title_sort | atad2 interacts with c/ebpβ to promote esophageal squamous cell carcinoma metastasis via tgf-β1/smad3 signaling |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7986551/ https://www.ncbi.nlm.nih.gov/pubmed/33757572 http://dx.doi.org/10.1186/s13046-021-01905-x |
work_keys_str_mv | AT caolianjing atad2interactswithcebpbtopromoteesophagealsquamouscellcarcinomametastasisviatgfb1smad3signaling AT zhangyijun atad2interactswithcebpbtopromoteesophagealsquamouscellcarcinomametastasisviatgfb1smad3signaling AT dongsiqi atad2interactswithcebpbtopromoteesophagealsquamouscellcarcinomametastasisviatgfb1smad3signaling AT lixizhao atad2interactswithcebpbtopromoteesophagealsquamouscellcarcinomametastasisviatgfb1smad3signaling AT tongxiating atad2interactswithcebpbtopromoteesophagealsquamouscellcarcinomametastasisviatgfb1smad3signaling AT chendong atad2interactswithcebpbtopromoteesophagealsquamouscellcarcinomametastasisviatgfb1smad3signaling AT wuziyi atad2interactswithcebpbtopromoteesophagealsquamouscellcarcinomametastasisviatgfb1smad3signaling AT zhengxiaohui atad2interactswithcebpbtopromoteesophagealsquamouscellcarcinomametastasisviatgfb1smad3signaling AT xuewenqiong atad2interactswithcebpbtopromoteesophagealsquamouscellcarcinomametastasisviatgfb1smad3signaling AT jiaweihua atad2interactswithcebpbtopromoteesophagealsquamouscellcarcinomametastasisviatgfb1smad3signaling AT zhangjiangbo atad2interactswithcebpbtopromoteesophagealsquamouscellcarcinomametastasisviatgfb1smad3signaling |